Medical
The drugmaker that hopes to legalize MDMA is cutting 75% of its staff after the FDA rejected the drug
Lykos will cut 75% of its staff, or about 100 employees, and the remaining team will focus on working with the FDA, the company said.
- Lykos Therapeutics is cutting 75% of staff after FDA rejected its MDMA drug for mental health.
- The FDA's decision ma… [+1998 chars]
Related
